AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) traded up 0.8% during trading on Tuesday . The stock traded as high as $1.27 and last traded at $1.27. 200 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 250 shares. The stock had previously closed at $1.26.
AB Science Price Performance
The company’s fifty day moving average price is $1.26 and its 200 day moving average price is $1.31.
About AB Science
AB Science SA, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.
Further Reading
- Five stocks we like better than AB Science
- 5 discounted opportunities for dividend growth investors
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- How to Use the MarketBeat Excel Dividend Calculator
- Is American Express the Credit Stock For a K-Shaped Economy?
- What is the Dow Jones Industrial Average (DJIA)?
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
